Fig. 4.

Probabilities, based on baseline DS3 severity status (marked, moderate or mild), of living free of a a new episode of avascular necrosis, fracture or lytic bone lesion once GD1 treatment is begun [log-rank test for the difference among groups: P = 0.0007], b living free of a new episode of avascular necrosis or lytic bone lesion once GD1 treatment is begun (fracture events excluded [log-rank test for the difference among groups: P < 0.0001])